ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and treatment"

  • Abstract Number: 2126 • 2012 ACR/ARHP Annual Meeting

    Changes of Serological Markers in the Course of Traditional and Biological Disease Modifying Therapy of Rheumatoid Arthritis

    Christoph Böhler1, Helga Radner2, Josef S. Smolen3 and Daniel Aletaha4, 1Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) are established markers in the diagnostic approach to rheumatoid arthritis (RA). Both auto-antibodies (AAB) also…
  • Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting

    The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort

    Stéphanie Emilie1, Cécile Gaujoux-Viala2, Benjamin Granger3, Anne-Christine Rat4, Bernard Combe5 and Bruno Fautrel6, 1Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, 2Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, 3Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, 4CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 5Rheumatology, Hopital Lapeyronie, Montpellier, France, 6Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France

    Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…
  • Abstract Number: 1842 • 2012 ACR/ARHP Annual Meeting

    Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America

    Sameer Kotak1, Andrew S. Koenig2, David H. Collier3, Katherine C. Saunders4, Ping He5, Joel M. Kremer6 and George W. Reed7, 1Specialty Care, Pfizer Inc., New York, NY, 2Specialty Care, Pfizer Inc, Collegeville, PA, 3Amgen Inc., Thousand Oaks, CA, 4Corrona, LLC., Southborough, MA, 5UMASS Medical School, Worcester, MA, 6Albany Medical College and The Center for Rheumatology, Albany, NY, 7University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Studies on patients with severe rheumatoid arthritis (RA) are widely reported. However, limited data are available on patients with moderate disease activity (MOD). Recent…
  • Abstract Number: 1327 • 2012 ACR/ARHP Annual Meeting

    Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea

    Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose:  The previous studies reported that intensive treatment-strategies, including biological agents and glucocorticoids, can improve the severity of early rheumatoid arthritis. However, there was no…
  • Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

    Steven De Bruyn1, Béla Gachályi2, Bernadette Rojkovich3, Slavomir Bruk4, Petr Sramek5, Mariusz Korkosz6, Krzysztof Krause7, Pieter Schoen8, Laura Sargentini-Maier9, Joke D'Artois10, Katrien Verschueren10, Katelijne De Swert10, Gerhard Arold11 and Josefin-Beate Holz12, 1Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, 2Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, 3II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, 4Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, 5Pharmaceutical Research Associates CZ, Praha, Czech Republic, 6Malopolskie Centrum Medyczne, Krakow, Poland, 7Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, 8Project Management, Ablynx N.V., Zwijnaarde, Belgium, 9Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 10Clinical Development, Ablynx nv, Zwijnaarde, Belgium, 11Medical Affairs, PRA International GmbH, Berlin, Germany, 12Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
  • Abstract Number: 983 • 2012 ACR/ARHP Annual Meeting

    Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

    Jing Cui1 and International RA Consortium on Therapy (InteRACT)2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Immunology and Allergy and Division of Genetics, Boston, MA

    Background/Purpose:  There are no biomarkers that predict response to anti-TNF therapy in rheumatoid arthritis (RA).  Here, we conduct a genome-wide association study (GWAS) to identify…
  • Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy

    Edward Bernton1, Eduard Krantz2 and William Gannon Jr.3, 1Protalex Inc., Summit, NJ, 2Parexel Clinical Pharmacology, Bloemfontein, South Africa, 3Capital City Technical Consulting, Inc., Washington, DC

    Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology